Boston Scientific (BSX)
Builds minimally invasive devices for cardiovascular, endoscopic, urological and neuromodulation procedures.
Something off on this page? Send us feedback.
Develops minimally invasive devices for cardiovascular, endoscopic, urological and neurological procedures, earning revenue from sales to hospitals, physicians and other care providers worldwide. Cardiovascular accounts for most sales, led by platforms spanning electrophysiology, left-atrial-appendage closure and interventional cardiology.
Develops and sells minimally invasive medical devices used in cardiovascular and MedSurg procedures. The Cardiovascular segment spans electrophysiology, WATCHMAN left-atrial-appendage closure, cardiac rhythm management, interventional cardiology and vascular therapies, and interventional oncology and embolization. MedSurg covers endoscopy, urology and neuromodulation.
Growth is built around new-product launches and acquired platforms, with FARAPULSE pulsed-field ablation a recent driver. Hospitals, physicians and other healthcare providers purchase the devices, while the United States supplies most sales and international markets provide the balance.
Commercialization depends on clinical evidence, regulatory clearance and country-specific reimbursement. Manufacturing also relies on some custom or single-source components, and medical-device rules govern product design, production, labeling, distribution and post-market monitoring.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | Oppenheimer | Reiterate | Rating: —Target: $85 | Target: $65 |
| Sep 17, 2026 | Citigroup | Downgrade | ||
| Sep 9, 2026 | BTIG | Reiterate | Rating: —Target: $60 | Target: $56 |
| Jul 31, 2026 | Argus Research | Downgrade | ||
| Jul 30, 2026 | RBC Capital | Reiterate | Rating: —Target: $85 | Target: $70 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $539.0M · Total debt $12.62B · Total assets $45.22B · Shareholders' equity $24.93B
- Revenue
- $5.44B
- Operating income
- $1.18B
- Net income
- $907.0M
No dividends on record.
| Institutions | 92.39% | 1.34B shares | |
|---|---|---|---|
| 1,573 holders · as of Jun 30, 2026 | |||
| Insiders | 0.18% | 2.61M shares | |
| 23 holders · as of Sep 3, 2026 | |||
| Other | 7.43% | 107.73M shares | |
| remainder | |||
1.45B company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.95% | 129.68M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.70% | 97.09M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.84% | 70.11M | as of Jun 30, 2026 |
Primecap Management Co/CA/Institution | 3.49% | 50.52M | as of Jun 30, 2026 |
FMR LLCInstitution | 3.15% | 45.70M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Susan E. Morano | director | +2,040 | $49.22 |
| Aug 5, 2026 | David C. Habiger | director | +2,100 | $47.59 |
| Aug 3, 2026 | Michael F. Mahoney | director, officer: Chairman, President & CEO | +186,240 | $48.33 |
| Aug 3, 2026 | David C. Habiger | director | +1,042 | $48.07 |
| Aug 4, 2026 | David C. Habiger | director | +140 | $48.59 |
- Medtronic
Widest rival footprint: EP, CRM, structural heart, neuromodulation, peripherals.
- Johnson & Johnson
Biosense Webster EP leader; Shockwave IVL adds peripheral vascular competition.
- Abbott
Multi-front rival: EP pipeline, top-selling DES, LAA closure, and SCS.
- Edwards Lifesciences
Pure-play structural heart leader; SAPIEN TAVR contests BSX cathlab access.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Boston Scientific | $44.74 | −0.40% | $66.77B | 18.3 | 13.6 | 3.2 | +7.5% |
| Medtronic | $90.06 | −0.78% | $116.19B | 22.4 | 15.0 | 3.1 | +13.7% |
| Johnson & Johnson | $268.42 | −0.29% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| Abbott | $104.03 | +0.29% | $179.49B | 33.4 | 18.0 | 3.9 | +13.0% |
| Edwards Lifesciences | $87.75 | −1.16% | $51.12B | 51.0 | 28.0 | 7.8 | +13.6% |
| Median | 32.3 | 20.3 | 5.2 | +13.3% |